Introduction: Malignant neoplasms of the rectosigmoid junction represent a significant subset of colorectal cancers, occurring at the transition between the sigmoid colon and rectum. These tumors are characterized by abnormal and aggressive cell growth and commonly present symptoms such as changes in bowel habits, rectal bleeding, abdominal pain, and signs of intestinal obstruction. These symptoms often lead patients to seek urgent medical care, resulting in high hospitalization rates. Analyzing the epidemiological profile of these hospitalizations is essential to identify trends in incidence, demographic characteristics, and healthcare demands, thereby supporting early detection strategies, hospital management, and public health planning. Objective: To analyze the epidemiological profile of hospitalizations due to malignant neoplasms of the rectosigmoid junction in Brazilian regions from 2017 to 2024. Methods: This is a descriptive, retrospective, and quantitative study based on data collected from the SUS Hospital Information System (DATASUS) and the National Cancer Institute (INCA). The study covers the period from 2017 to 2024 and analyzes variables such as the number of hospitalizations, type of admission (elective or emergency), age group, gender, and geographic distribution across Brazil’s North, Northeast, Midwest, Southeast, and South regions. Results: Between 2017 and 2024, a total of 277,669 hospitalizations occurred in Brazil, with the highest number in 2024 (40,346). There was a general upward trend, except in 2019 (33,218) and 2020 (31,267), likely due to the impact of the COVID-19 pandemic. The Southeast had the highest proportion of hospitalizations (47.7%), followed by the South (28.3%), Northeast (15.7%), Midwest (5.5%), and North (2.7%). Emergency admissions accounted for 51%, surpassing elective ones (49%) in all regions except the Northeast. The 60–69 age group had the highest number of hospitalizations (85,856), with a progressive increase up to that range, followed by a decline in the older age groups. Males (146,312) were hospitalized more than females (131,357), except in the North and Northeast regions. Conclusion: Understanding the hospitalization patterns for colorectal cancer is crucial, as it is the second most common type of cancer and the third leading cause of cancer-related deaths in Brazil. Regional differences reflect the country’s sociodemographic disparities. The most affected group consists of men aged 60 to 69. The decline in hospitalizations in 2019 and 2020 is attributed to the COVID-19 pandemic, while the increase in subsequent years reflects the rising global cancer incidence.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
